Triple Therapy Benefit in Chronic Obstructive Pulmonary Disease

Treatment for chronic obstructive pulmonary disease (COPD) traditionally has been inhaled corticosteroids, long-acting beta agonists, or long-acting muscarinic antagonists. These agents can be used alone or in combination, depending on the severity of patient symptoms, eosinophil count, and exacerbation risk. Dr MeiLan Han, of the University of Michigan, discusses results from the IMPACT and ETHOS trials, which show that triple therapy provides benefit in highly symptomatic, high-risk patients who are not responding to dual therapy. Patients taking triple therapy had fewer COPD exacerbations, fewer symptoms, lower rates of hospitalization, and improved lung function.

Dr Han also reports that a survival benefit was seen with triple therapy in both IMPACT and ETHOS.

Medscape © 2020 WebMD, LLC

Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.

Cite this: Triple Therapy Benefit in Chronic Obstructive Pulmonary Disease - Medscape - Aug 26, 2020.